Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Chinedu Ike-Morris"'
Autor:
Emily Saintas, Liam Abrahams, Gulshan T Ahmad, Anu-Oluwa M Ajakaiye, Abdulaziz S H A M AlHumaidi, Candice Ashmore-Harris, Iain Clark, Usha K Dura, Carine N Fixmer, Chinedu Ike-Morris, Mireia Mato Prado, Danielle Mccullough, Shishir Mishra, Katia M U Schöler, Husne Timur, Maxwell D C Williamson, Markella Alatsatianos, Basma Bahsoun, Edith Blackburn, Catherine E Hogwood, Pamela E Lithgow, Michelle Rowe, Lyto Yiangou, Florian Rothweiler, Jindrich Cinatl, Richard Zehner, Anthony J Baines, Michelle D Garrett, Campbell W Gourlay, Darren K Griffin, William J Gullick, Emma Hargreaves, Mark J Howard, Daniel R Lloyd, Jeremy S Rossman, C Mark Smales, Anastasios D Tsaousis, Tobias von der Haar, Mark N Wass, Martin Michaelis
Publikováno v:
PLoS ONE, Vol 12, Iss 2, p e0172140 (2017)
The formation of acquired drug resistance is a major reason for the failure of anti-cancer therapies after initial response. Here, we introduce a novel model of acquired oxaliplatin resistance, a sub-line of the non-MYCN-amplified neuroblastoma cell
Externí odkaz:
https://doaj.org/article/ef8bcb9439b04f71b952d9ed30ce9beb
Autor:
Emma Hargreaves, Daniel R. Lloyd, Gulshan T Ahmad, Michelle D. Garrett, Jeremy S. Rossman, Catherine E.M. Hogwood, Candice Ashmore-Harris, Anastasios D. Tsaousis, Usha K Dura, Mark N. Wass, Richard Zehner, Markella J. Alatsatianos, Iain Clark, Michelle L. Rowe, Mireia Mato Prado, Maxwell D C Williamson, Edith Blackburn, Shishir Mishra, William J. Gullick, Tobias von der Haar, Florian Rothweiler, Pamela E Lithgow, Martin Michaelis, Emily Saintas, Basma Bahsoun, Abdulaziz S H A M AlHumaidi, Darren K. Griffin, Campbell W. Gourlay, Lyto Yiangou, Katia M U Schöler, Anthony J. Baines, Carine N Fixmer, Liam Abrahams, C. Mark Smales, Chinedu Ike-Morris, Jindrich Cinatl, Danielle Mccullough, Mark J. Howard, Anu-Oluwa M Ajakaiye, Husne Timur
Publikováno v:
PLoS ONE
PLoS ONE, Vol 12, Iss 2, p e0172140 (2017)
PLoS ONE, Vol 12, Iss 2, p e0172140 (2017)
The formation of acquired drug resistance is a major reason for the failure of anti-cancer therapies after initial response. Here, we introduce a novel model of acquired oxaliplatin resistance, a sub-line of the non-MYCN-amplified neuroblastoma cell